Citi Pharma Ltd. CPHL
Rs 72.45
Vol306,197Updated12:2919 Aug 2026
01—At a Glance
The headline take on CPHL — valuation, income, returns, and efficiency
Consolidated snapshot
02—Price & Performance
Closing prices across timeframes, returns, and range context
CPHL — Price History
Daily closing series · toggle period below
03—Key Metrics
Valuation, profitability, structure, and risk in one grid
04—Dividend History & Yield
Payout track record, yield trend, and upcoming distribution
CPHL has paid Rs 3.50 per share in cash dividends over the trailing 12 months — a 4.8% yield at the last close. Its most recent payout was Rs 3.50/share, announced 02 Oct 2025 with book closure from 21 Oct 2025. Annual dividend-per-share history back to 2016 is charted below.
Latest Payout
Dividend Per Share Trend
Payout History
Source: PSX company payouts
| Announced | For Period | Type | Amount | Book Closure |
|---|---|---|---|---|
| 02 Oct 2025 | 30 Jun 2025 (YR) | Cash | Rs 3.50(35%) | 21 Oct 2025 – 27 Oct 2025 |
05—Financials & Earnings
Income, balance sheet, and key ratios from published accounts
CPHL's market capitalisation stands at Rs 16.60B as of 18 Aug 2026 — down 17.4% over the past 12 months (from Rs 20.10B).
Financial Statements
How CPHL's income and balance sheet have evolved
| PKR Millions | Mar-26 | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 | Jun-24 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales / Revenue | 3,085 | 4,333 | 3,370 | 3,053 | 3,341 | 3,534 | 3,225 | 2,874 | |
| Cost of Sales | 2,562 | 3,375 | 2,851 | 2,492 | 2,852 | 2,995 | 2,796 | 2,631 | |
| Gross Profit | 523 | 958 | 519 | 561 | 489 | 539 | 429 | 243 | |
| Administrative Expenses | 54 | 62 | 48 | 61 | 57 | 58 | 46 | 49 | |
| Operating Profit | 408 | 826 | 420 | 429 | 396 | 438 | 342 | 118 | |
| EBITDA | 442 | 883 | 467 | 478 | 452 | 460 | 383 | 164 | |
| Other Income | 23 | 28 | 29 | 33 | 23 | 50 | 92 | 177 | |
| Financial Charges | 80 | 81 | 121 | 98 | 99 | 68 | 65 | 99 | |
| Profit Before Tax | 326 | 724 | 302 | 326 | 294 | 394 | 340 | 164 | |
| Taxation | 51 | 319 | 99 | 113 | 74 | 137 | 139 | 11 | |
| Profit After Tax | 275 | 404 | 204 | 214 | 220 | 257 | 201 | 153 | |
| EPS - Basic (Rs) | Rs 1.21 | Rs 1.77 | Rs 0.89 | Rs 0.94 | Rs 0.96 | Rs 1.12 | Rs 0.88 | Rs 0.67 |
Showing 8 of 8 quarters · scroll horizontally to see more periods.
All figures in PKR millions from published accounts.
Profitability & Returns
Margins, returns on capital, and earnings per share
Latest · Mar-26
| Ratio | Value |
|---|---|
| Net profit margin | 8.9% |
| Gross profit margin | 17.0% |
| EBITDA margin | 14.3% |
| EBIT margin | 13.2% |
Net profit margin
Net profit ÷ revenue · %
Financial Health
Coverage, leverage, and the strength of the balance sheet
Latest · Mar-26
| Ratio | Value |
|---|---|
| Current ratio | 1.31 |
| Quick ratio | 0.59 |
| Cash ratio | 0.04 |
| Asset turnover | 0.16x |
| Effective tax rate | 15.6% |
Current ratio
Current assets ÷ current liabilities
Market cap trajectory
Close × current shares outstanding · current Rs 16.60B
Valuation & Capital Returns
What the market is paying for CPHL, and what it returns to shareholders
Latest · Mar-26
| Ratio | Value |
|---|---|
| Price to earnings | 60.26x |
| Price to book | 1.52x |
| EV / EBITDA | 44.89x |
| Price to sales | 5.40x |
Price to earnings
Period-end price ÷ EPS · times
06—Technical Analysis
Trading signal, moving averages, momentum, and key levels
10-day SMA (Rs 73.86) is below the 30-day SMA (Rs 75.04). RSI at 38 sits in the neutral band.
Moving AverageThe average close over a set window (10/30/200 days) — smooths daily noise to reveal the trend.Read the full guide →
| Period | Value | vs Current | Position |
|---|---|---|---|
| SMA 10 | Rs 73.86 | +1.94% | Below |
| SMA 30 | Rs 75.04 | +3.58% | Below |
| SMA 60 | Rs 76.85 | +6.08% | Below |
| SMA 200 | Rs 80.94 | +11.72% | Below |
At 38, momentum sits within the neutral band (30–70), suggesting balanced buying and selling pressure.
- MACD-1.02
- Signal-0.98
- Histogram-0.04
07—Leverage Insights
MTS, margin financing, futures open interest, and combined exposure
Leverage Composition
MTS · MFS stacked over the selected window
As of 18 Aug 2026
No blank sales
No net blank (short) sales reported for CPHL on the latest PSX DFC report.
08—Settlement Insights
UIN-wise settlement concentration and price context
Metrics and charts over the selected trailing window
Settlement % Trajectory
Solid = UIN settlement % · Dashed = 14-session EMA
As of 18 Aug 2026
Price vs Settlement
Close price (left axis) · UIN settlement % (right axis)
10—About the Company
Business description, governance, and corporate information
Citi Pharma Limited incorporated as a private limited company in Pakistan under the repealed Companies Ordinance, 1984 on October 08, 2012. The principal activity of the company is manufacturing and sale of pharmaceuticals, medical chemicals and botanical products.
Corporate Information
- RegistrarF.D Registrar Services (Pvt.) Ltd.
- AuditorAslam Malik & Co. Chartered Accountants
- Websitewww.citipharma.com.pk
- Address3-KM, Head Balloki Road, Bhai Pheru, Distt Kasur
- SectorPharmaceuticals
- Financial Year EndJune
Key People
| Name | Role |
|---|---|
RARizwan Ahmad | CEO |
NANadeem Amjad | Chairperson |
MRMuhammad Rasheed Alam | Company Secretary |
Reports & Filings
- Quarterly Report — 31 Mar 2026PDF
- Quarterly Report — 31 Dec 2025PDF
- Quarterly Report — 30 Sept 2025PDF
- Quarterly Report — 31 Mar 2025PDF
- Annual Report FY2025PDF
- Quarterly Report — 31 Dec 2024PDF
- Quarterly Report — 30 Sept 2024PDF
- Quarterly Report — 31 Mar 2024PDF
Sourced from official PSX financial-report submissions.
11—Recent Announcements
Latest company filings as reported on PSX
Filings and disclosures from the PSX announcement feed
- 10 Aug 2026Insider TradingDisclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations
- 07 Aug 2026Other
- 09 Jul 2026General Meeting
- 09 Jul 2026General Meeting
- 08 Jul 2026Material Information
- 01 Jul 2026Board Meetings
- 15 Jun 2026Board Meetings
- 21 May 2026Others
12—Peers in Pharmaceuticals
How the cohort is moving — same-sector stocks by market cap
CPHL vs Pharmaceuticals sector median
| Metric | CPHL | Sector median |
|---|---|---|
| P/E RatioShare price ÷ earnings per share — the price you pay for each rupee of annual profit. Compare within a sector.Read the full guide → | 18.6x | 15.3x |
| Dividend YieldTrailing-12-month cash dividends ÷ share price. A high yield can signal income — or a falling price.Read the full guide → | 4.8% | 4.1% |
| Return on EquityNet profit ÷ shareholders' equity — how hard the company works each rupee investors have put in.Read the full guide → | — | 22.3% |
| 1-Year Return | -16.8% | -15.9% |
| Market CapitalisationShare price × total shares — the company's full market value, and the basis for index weightings.Read the full guide → | Rs 16.60B | Rs 27.59B |
Pharmaceuticals · sector heat
13—Frequently Asked Questions
The most common questions investors ask about CPHL
Frequently Asked Questions
CPHL is trading at Rs 72.45, down 0.29% on the day, within a 52-week range of Rs 69.25–104.25, from the 15-minute snapshot taken at 12:30 PKT. Prices on this page refresh every 15 minutes during market hours; log in to BSL for live quotes.
Citi Pharma Limited incorporated as a private limited company in Pakistan under the repealed Companies Ordinance, 1984 on October 08, 2012. See About the Company on this page for the full profile, management, and corporate information.
CPHL has paid Rs 3.50 per share in cash dividends over the trailing 12 months — a 4.8% yield at the last close. Review the payout history in the Dividends section and compare with the highest dividend yield stocks on PSX.
No upcoming payout is announced yet. The most recent was a payout of Rs 3.50 per share with book closure from 21 Oct 2025. New announcements appear on this page and on the PSX ex-dates calendar.
Yes — Citi Pharma Ltd. is on the PSX's Shariah-compliant (KMI All Shares) list and is a KMI-30 constituent; it also belongs to the KSE-100. Browse all Shariah-compliant PSX stocks.
CPHL trades at 18.6x earnings against a Pharmaceuticals median of 15.3x, with a 4.8% dividend yield versus 4.1%. The full comparison table and peer list are in the Peers section, or explore the Pharmaceuticals sector page.
Annual reports for FY2025 are linked under Reports & Filings in the About section of this page, sourced from official PSX submissions.
Open a BSL trading account, fund it, and place your CPHL order on the Pakistan Stock Exchange — account opening takes minutes online, with PSX execution, research, and concierge support included.
Quotes and metrics refresh on a regular cadence through the trading day and after the close. For streaming real-time PSX prices and order placement, log in to your BSL account.
Ready to invest in CPHL?
Open a BSL trading account in under 10 minutes
Buy and sell CPHL and every other PSX-listed stock with low commissions, real-time data, and a concierge research desk backing every trade.